Yimiao Shenzhou Completes Series E Financing of Several Hundred Million RMB to Advance Commercialization of Its First-in-Class CAR-T Therapy IM19
Imunopharm
Developer of Gene and Cell Therapy Technologies
Click on the image to register for free2025 IBI EXPO
January 9, 2025
eMedClub News
On January 8, in Beijing, China, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. (referred to as "Yimiaoshenzhou") announced the official completion of its Series E financing round worth hundreds of millions of RMB.This round of financing was led by the Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund., Taiping Healthcare Fund, Capital Development Group, Sijiqing Investment, Sunshine Nuohé, and other professional institutions followed suit with investments. This is Beijing Yimiaoshenzhou Medical Techology Co., Ltd.Completed on the 10th Anniversary of EstablishmentThe 10th Round of Strategic Financing, marking a significant milestone and a new starting point as the company advances from clinical trials to commercialization after a decade of dedication to the field of independently developed gene and cell therapies.
The press release noted that the funds from this round of financing will be used to support the commercialization layout of its first self-developed CAR-T new drug, IM19.To drive the approval of this drug and establish it as a benchmark CAR-T treatment for advanced lymphoma in China, providing patients with a new treatment option;At the same time, the company will also accelerate the research and development as well as clinical progress of new processes and products in major disease areas such as hematological tumors, solid tumors, and autoimmune diseases., to help build China's leading next-generation gene and cell drug technology platforms, such as rapid CAR-T, universal CAR-T, and gene editing, and to advance the establishment of an industry-leading large-scale GMP production and manufacturing base, injecting strong momentum into the company’s development.
[Currently, China's biopharmaceutical industry is still in a "winter" period. In order to promote the industrial development of biopharmaceuticals, facilitate the rapid growth of high-quality innovative biomedicine projects, and achieve effective alignment with capital, a conference jointly organized by MedChina and Biobay is being held.]The 5th Biopharmaceutical Innovation Financing Roadshow & Investment ForumIt will be held on March 1, 2025, at the Suzhou International Expo Center (G Hall). More than 56 investment institutions, including Qiming Venture Partners and WinX Capital, are expected to attend this sub-forum. Everyone is welcome to scan the code to register and participate.】
2025 (3rd) Biopharmaceutical Innovation Industry Conference
Pre-registration Opened
Investment Institutions Expected to Attend in Person
2025 IBI EXPO
Dr. He Ting, CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., stated: "We are very grateful for the recognition and support from both new and existing shareholders. This round of financing is an important milestone in the 10-year development journey of Yimiao Shenzhou. We will take this as an opportunity to fully advance the commercialization of our first CAR-T product, IM19, as well as the research and development layout of CAR-T treatment products covering major diseases such as hematological tumors, solid tumors, and autoimmune diseases. We will continue to invest in the research and development of next-generation CAR-T processes and technologies, promote technological iteration and upgrading, ensuring that Yimiao Shenzhou maintains a leading position in the global gene and cell drug competition. Our goal is to research and produce more new and effective drugs with lower costs, better efficacy, and higher safety, benefiting a wide range of patients, promoting industrial development, and serving Healthy China."”
The Beijing-Tianjin-Hebei Collaborative Development Industry Investment Fund stated: "As an investment fund focused on the coordinated development of the Beijing-Tianjin-Hebei region, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. has demonstrated technological innovation and industrialization capabilities in the field of gene and cell drugs.In line with our strategy of supporting high-tech, high-growth enterprisesWe believe that through this collaboration, it will not only accelerate the rapid development of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., but also contribute significantly to the coordinated development of the cell therapy industry in the Beijing-Tianjin-Hebei region and the rise of China's cell therapy industry.”
About Yimiao Shenzhou
Yimiao Shenzhou, established in 2015 with its headquarters in Beijing, is a leading innovative pharmaceutical company at the commercialization stage. With the mission of "making cancer no longer an incurable disease," it focuses on applying cutting-edge gene and cell drug technologies to the treatment of major diseases such as cancer and autoimmune disorders.
As of now,Yimiao ShenzhouCompleted 10 rounds of strategic financing, owns a one-stop independent gene and cell drug R&D and industrialization platform, and possesses multiple core technologies. Awarded the highest prize in the finals of China's Disruptive Technology Innovation Competition, it has received clinical trial approvals for seven Category 1 new drugs and Beijing’s first Manufacturing License for gene and cell drugs. Its R&D pipeline covers hematological tumors such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, and melanoma, making it a leading enterprise in gene and cell drugs.
References:
[1]Yimiao ShenzhouOfficial Weibo
Welcome everyone to register for the 2025 IBI EXPO conference and keep pace with the times. Below is the 2024 IBI EXPO.Video Highlights of the Event.
Registration and Event Consultation
IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceWillMarch 1, 2025 to March 2, 2025InSuzhou International Expo CenterGrandly held. The theme of the conference isCollaboratively Building the Entire Chain, Innovating and Transforming the New Ecosystem。
The conference will invite300+Guest Speaker, Opening30+Forum events, covering hundreds of hot topics, aroundCell and Gene Therapy, Radiopharmaceuticals, Antibody Innovation Conjugation, Targeted Protein Degradation, Stem Cell Regeneration, mRNA Vaccines and Nucleic Acid Drugs, Exosomesetc.New Molecular Drugs,AI Drug Discovery, Organoids, Novel Delivery Vectorsetc.Cutting-edge Technology，Engage in exchange and discussion, and collaboratePharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsBy leveraging multiple forces, we can drive the transformation of cutting-edge innovations from scientific research to industrial applications, injecting a source of development into the biopharmaceuticals market.
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media:Teacher Wang 18717836231
DianDian "Share”、“Like" and "In View"，Give me a little recharge~